Andrew has served as a member of our board since July 2018. He currently serves as Chief Financial Officer of Dermira, Inc., a public biopharmaceutical company focused on medical dermatology. Previously, Andrew served as Chief Financial Officer of CardioDx, Inc., a molecular diagnostics life sciences company, from September 2011 to April 2014, and as a member of the CardioDx board of directors from April 2014 until July 2016. From September 2010 to April 2011, he served as Chief Financial Officer of Calistoga Pharmaceuticals, Inc., a biotechnology company acquired in April 2011 by Gilead Sciences, Inc. From December 2008 to June 2010, Andrew served as Senior Vice President and Chief Financial Officer of Facet Biotech Corporation. Facet Biotech Corporation was spun off from PDL BioPharma, Inc. where he served as Senior Vice President and Chief Financial Officer from April 2006 to December 2008. From October 2000 to March 2006, Andrew served as Chief Financial Officer of Neoforma, Inc., a provider of supply-chain management solutions for the healthcare industry. From January to October 2000, he served as Neoforma’s Vice President, Corporate Development. Andrew began his career in financial services at Merrill Lynch & Co. and Wells Fargo & Company. He holds a B.A. in International Politics and Economics from Middlebury College and holds an MBA. from the J.L. Kellogg Graduate School of Management at Northwestern University.